Kiniksa Pharmaceuticals International, plc Class A KNSA
NASDAQ · United States · Health Technology
$75.71+1.10 (+1.47%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momentum for Kiniksa Pharmaceuticals International has cooled a little, with the share price down over the past month. However, the 90 day share price return of 33.73% and year to date gain of 81.12% point to a strong upswing overall. Compare Kiniksa...
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.